1.1 The Clinical Trial Ecosystem video lecture

1.1 The Clinical Trial Ecosystem

1.2 The trial life cycle video lecture

1.2 The trial life cycle

1.3 What does a clinical operation professional do?

2.1 The Trial Master File: Purpose and Importance

2.2 The DIA TMF Reference Model

2.3 The Investigator Site File: Building and Maintaining Your ISF

he ISF must be set up before the first document arrives. A structure created in advance turns filing into a simple daily task. A structure created retroactively is always incomplete. 2 Every document version must be retained. When a protocol, ICF, IB, or any other versioned document is updated, the previous version stays in the ISF marked as superseded. Nothing is discarded. 3 Backdating is a critical violation. Every document entry must reflect the actual date it was signed, received, or completed. The Delegation of Authority Log in particular must be updated on the day of any change, never backdated. 4 Close-out is not a formality. It is one of the most document-intensive stages of the trial. IP must balance to zero, all deviations must be closed, and notifications must be sent. An uncompleted close-out creates lasting compliance risk. 5 The archive obligation survives the end of the trial and the departure of the PI. Documents must be retained, protected, and accessible for the full retention period. No documents may be destroyed without written sponsor authorization.

2.4 eTMF Systems: Working with Electronic Trial Master Files

The shift from paper to eTMF does not change the principles of good document management. It changes the tools. Classification, version control, completeness, and timeliness are equally important in both systems. 2 The automated audit trail is the defining advantage of eTMF systems. Every action is timestamped and user-attributed in a tamper-evident record, removing reliance on human memory during inspections. 3 Metadata accuracy is as important as the document itself. An incorrectly classified document is invisible to completeness checks and creates errors in both the source and target zones. 4 In a hybrid paper and eTMF model, both the paper original and the eTMF upload must be maintained. Paper originals cannot be discarded without written sponsor authorization. 5 Most Arab investigational sites today operate a hybrid model. Mastering eTMF upload processes alongside paper ISF management is not a future skill. It is a current requirement for anyone working on international trials.

3.1 The Principal Investigator: Roles and Responsibilities

The PI is the single point of accountability at the site. All trial conduct, whether performed personally or delegated, remains the PI's responsibility under GCP. 2 Delegation transfers a task, not accountability. The PI must ensure delegated tasks are performed by qualified people and must provide ongoing supervision throughout the trial. 3 Some tasks cannot be delegated at all. The PI's personal signature on legally binding documents, protocol agreements, and investigator declarations must be given personally. These are not administrative tasks; they are personal commitments. 4 The PI must have adequate time. Agreeing to lead a trial without sufficient time to provide proper oversight is itself a GCP risk. Sponsors assess PI availability during feasibility and the SQV. 5 Backdating and proxy signing are never acceptable. If a document is signed late, the correct approach is to sign today with today's date and document the reason for the delay. False dates and false signatures are data integrity violations regardless of the reason behind them.

3.2 The Site Team: Delegation and Roles

GCP defines qualifications and responsibilities, not job titles. What matters is whether a person is qualified for a task and whether that task is properly documented on the Delegation of Authority Log. 2 Medical judgment cannot be delegated to non-clinical staff. SAE causality assessment, eligibility determination, and consent discussions require a medically qualified person. A CRC or data manager cannot perform these tasks regardless of experience. 3 No one performs a trial task before they are on the DoA Log. This is an absolute rule. Even a highly qualified sub-investigator cannot perform trial procedures without a current delegation entry signed by the PI. 4 Team changes must trigger immediate DoA Log updates. When someone joins or leaves the team, the delegation log must be updated before any change in who performs what tasks. There is no grace period. 5 The pharmacist cannot dispense without a valid prescription from an authorised delegated prescriber. This is both a GCP requirement and a professional pharmacy obligation. IP dispensing on an unauthorised instruction is a critical deviation.

3.3 The Delegation of Authority Log

The DoA Log is the documented basis for every delegated trial task. If a task is not on the log for that person, it has no authorisation under GCP, regardless of whether it was performed correctly. 2 Start dates must precede any delegated activity. A person cannot perform trial tasks before their entry date. Any mismatch between their DoA Log start date and actual task dates is a protocol deviation. 3 End dates must be recorded when a team member leaves. A closed delegation entry provides a clear audit trail and protects both the site and the departing person from being associated with activity that occurred after their departure. 4 Every person signs their own entry. Proxy signatures on the DoA Log are not acceptable. Each team member must sign personally to confirm they understand and accept their delegated responsibilities. 5 The DoA Log must be updated contemporaneously. Every team change, task change, or role change must be reflected in the log at the time it occurs, not weeks later during a monitoring visit preparation sprint.

4.1 The Feasibility Assessment: What Sponsors Want to Know

Sponsors are asking one question: Can this site enroll the right patients, collect reliable data, and stay compliant — on time? Every element of the feasibility questionnaire is a component of that answer. 2 Honest, evidence-based responses always outperform inflated promises. Sponsors have long memories. A site that overcommits and underdelivers will not be selected for future trials. A site that delivers on a conservative promise builds a lasting reputation. 3 First-time sites are not automatically disqualified. A well-prepared team with a strong patient population, current GCP training, developed SOPs, and a realistic response can be selected over an experienced but disorganized site. 4 Local regulatory knowledge is a competitive advantage. Sites that can explain their ethics committee process, give realistic timelines, and offer to submit early demonstrate local expertise that sponsors value highly in Arab country sites. 5 Your site's reputation is built one trial at a time. Enrolment performance, data quality, and communication habits from your current trials are creating the invisible asset or liability that will determine your feasibility scores for every future trial.

4.2 The Site Qualification Visit

The SQV is a professional presentation, not an inspection. The CRA is looking for reasons to select your site. Approach it with prepared confidence, not anxiety. 2 Gaps identified during the SQV do not automatically disqualify a site. Most sites have some pre-activation requirements. What matters is that you acknowledge them honestly and present a clear plan to resolve them. 3 Document readiness is the most controllable factor. Every essential document should be gathered and verified before the SQV. Arriving with expired certificates or missing documents is avoidable with good preparation. 4 The PI must know the protocol. A PI who cannot describe the main inclusion criteria, the primary endpoint, or the visit schedule during the opening meeting signals to the CRA that the site is not yet ready. 5 The final activation decision belongs to the sponsor. The CRA writes a report and submits it. The site team's job is to give the CRA the strongest possible evidence to include in that report.

4.3 Arab-Specific Regulatory Considerations

Every Arab country has its own regulatory authority and pathway. There is no single Arab regulatory body. Sites must know their own country's specific authority, submission requirements, and realistic timelines. 2 Most Arab countries require both a national regulatory approval and an institutional ethics committee approval. These can often be submitted in parallel to reduce the overall timeline to site activation. 3 Language is a critical factor in North African countries. Morocco and Tunisia require submission documents in Arabic or French. An English-only package will cause delays. Sites should inform sponsors of this requirement as early as possible. 4 Your local regulatory knowledge is a competitive advantage. Sponsors depend on site teams to navigate national requirements. A team that can give accurate timelines, explain the submission process, and anticipate local requirements will always be preferred over a team that says only "it depends." 5 Regulatory landscapes change. Authority names, submission requirements, and timelines evolve. Sites should maintain updated knowledge of their national regulatory requirements and subscribe to updates from their country's relevant authority.

5.1 ICH-GCP: The International Standard

5.2 Standard Operating Procedures (SOPs)

5.3 Protocol Deviations and Violations

5.4 Adverse Event Reporting in Clinical Operations

5.5 Inspection Readiness: Staying Ready Every Day

Capstone : Clinical Operations Site Readiness Dossier